Zobrazeno 1 - 10
of 882
pro vyhledávání: ''
Publikováno v:
Medical Oncology. 39
The favorable outcomes of venetoclax-based regimens in older adults with acute myeloid leukemia (AML) may result in its regimen becoming the standard treatment. However, the dosage of venetoclax is fixed, irrespective of body surface area (BSA) or we
Autor:
Marzieh Shirin, Sajedeh Madadi, Noshad Peyravian, Zahra Pezeshkian, Leili Rejali, Masoumeh Hosseini, Afshin Moradi, Binazir Khanabadi, Ghazal Sherkat, Hamid Asadzadeh Aghdaei, Ehsan Nazemalhosseini-Mojarad
Publikováno v:
Medical Oncology. 39
Different molecular signaling pathways have been involved in the incidence and progression of CRC. We aimed to examine the correlation between eight candidate genes, including TFGβ, SMAD2, SMAD4, RhoA, EGFR, MAP2K1, MTA1, and LEF1 in the progression
Publikováno v:
Medical Oncology. 39
Keynote-826 study demonstrated that the addition of pembrolizumab to standard systemic therapy contributes to progression-free and overall survival in patients with persistent, recurrent, or metastatic cervical cancer receiving chemotherapy with or w
Autor:
Chang-Xing Lyu, Xiao-Long Fu, Wan-Qin Zeng, Qin Zhang, Lan-ting Gao, Wentao Fang, Lei Zhu, Chang-lu Wang
Publikováno v:
Medical Oncology. 39
BackgroundThere are no optimal regimens for advanced thymic epithelial tumors (TETs) when front-line chemotherapy fails. In this study, we aimed to assess the activity of Bevacizumab in combination with routine chemotherapeutic regimen.MethodsPatient
Autor:
Eman Z. Kandeel, Mohamed A. Samra, Hend A Nooh, Lobna A. Refaat, Ahmed Bayoumi, Medhat Khafagy, Mona S Abdellateif
Publikováno v:
Medical Oncology (Northwood, London, England)
To assess the prognostic role of different inflammatory indices on the outcome of cancer patients with COVID-19. Sixty-two adults and 22 pediatric cancer patients with COVID-19 infection were assessed for the prognostic value of certain inflammatory
Autor:
V. Corset, Sandrine Paindavoine, David Meyronet, Marie Blonski, Emilie Lavergne, Sylvie Chabaud, Valéry Attignon, Jean-Yves Blay, Luc Taillandier, Sylvie Lantuejoul, François Ducray, Olivier Tredan, Didier Frappaz, Emilie Sohier, Christian Baudet, V. Agrapart, David Pérol, Christine Rodriguez, Daniel Pissaloux, Alice Bonneville-Levard, Qing Wang, Isabelle Treilleux, Alain Viari, Laure Thomas-Maisonneuve, Jérôme Honnorat, Stéphanie Cartalat
Publikováno v:
Medical Oncology
Medical Oncology, 2021, 39 (1), pp.4. ⟨10.1007/s12032-021-01536-4⟩
Medical Oncology, 2021, 39 (1), pp.4. ⟨10.1007/s12032-021-01536-4⟩
International audience; Immunohistochemistry and recent molecular technologies progressively guided access to personalized anti-tumoral therapies. We explored the feasibility, efficacy, and the impact of molecular profiling in patients with advanced
Autor:
Hilal Akalin, Abdulbaki Yildirim, Munis Dundar, Nilgun Karasu, Mikail Demir, Hande Kulak, Muzaffer Keklik, Serhat Çelik, Nuriye Gokce
Publikováno v:
Medical Oncology. 38
Imatinib mesylate, a tyrosine kinase inhibitor, is the first choice in chronic myeloid leukemia treatment. However, resistance to imatinib may develop with time and in some cases, patients may not respond at all to imatinib. Progressive resistance to
Autor:
Xiaona Sun, Runhong Ma, Panpan Liu, Xianling Feng, Yuxia Li, Ting Wang, Ting Cui, Xiujuan Wu, Xiaoliu Li, Yang Bai
Publikováno v:
Medical Oncology. 38
ATF3 is an essential transcription activator in regulating cancer-related genetic expression. To identify the role of ATF3 in ovarian tumor, we investigated the correlation between ATF3 expression and the clinicopathological properties using multiple
Publikováno v:
Medical Oncology. 38
The tumor microenvironment plays an important role in tumor development and progression, but the role of immune and stromal cells in this environment has not been sufficiently studied. In this study, we aimed to identify key genes associated with the
Publikováno v:
Medical Oncology. 38
Although various molecular subtypes of hepatocellular carcinoma (HCC) have been investigated, most of these studies identify HCC subtype based on genomic profiling. Few studies have investigated the classification based on immune signatures, and none